The surgeon: new surgical aproaches
|
|
- Emmeline Malone
- 5 years ago
- Views:
Transcription
1 The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical, pathological and legal features. Padua, November 8, 2012
2 Malignant pleural mesothelioma surgical treatment surgical techniques, definitions pleurectomy/decortication extrapleural pneumonectomy recent surgical studies EORTC MARS 1 pilot trial surgery: quo vadis?
3 Malignant pleural mesothelioma surgical treatment surgical techniques, definitions pleurectomy/decortication extrapleural pneumonectomy recent surgical studies EORTC MARS 1 pilot trial surgery: quo vadis?
4 Surgical techniques Pleurectomy / decortication removal involved parietal + visceral pleura + resection diaphragm, pericardium if necessary preservation of lung parenchyma
5 Surgical techniques Pleurectomy / decortication advantages disadvantages low mortality morbidity preservation of lung parenchyma good palliation subsequent therapy rapidly possible - adjuvant chemoradiotherapy reduced radiation dose only radical for early stages Maggi G. Trimodality management of malignant pleural mesothelioma. EJCTS 2001; 19:346-50
6 Surgical techniques EPP : extrapleural pneumonectomy removal parietal pleura ipsilateral lung pericardium if necessary diaphragm if necessary reconstruction diaphragm, pericardium : PTFE soft tissue patch Sugarbaker D. J Thorac Cardiovasc Surg 2004; 128:138-46
7 Surgical techniques EPP : extrapleural pneumonectomy advantages maximal debulking procedure postop. radiation dose good palliation disadvantages major operation mortality morbidity survival advantage?
8 Technique of extrapleural pneumonectomy
9 Technique of extrapleural pneumonectomy pericardial patch diaphragm patch
10 Technique of extrapleural pneumonectomy pericardial patch diaphragm patch
11 Technique of extrapleural pneumonectomy intercostal muscle flap pericardial patch
12 Recommendations for uniform definitions of surgical techniques MPM
13 Malignant pleural mesothelioma surgical treatment surgical techniques, definitions pleurectomy/decortication extrapleural pneumonectomy recent surgical studies EORTC MARS 1 pilot trial surgery: quo vadis?
14 EORTC Phase II feasibility trial registration pathologically proven MPM ct3n1m0 or less (UICC TNM) induction chemotherapy 3 cycles cisplatin 75 mg/m 2 Q 21 days + pemetrexed 500 mg/ m 2 Response evaluation preferably at the end of induction chemotherapy or after at least 2 cycles
15 EORTC Phase II feasibility trial if - no progressive disease - no unacceptable toxicity extrapleural pneumonectomy (EPP) within 21 to 56 days after last dose of chemotherapy postoperative radiotherapy (54 Gy) 30 days after surgery but within 84 days 3D planning/total dose of 54 Gy (30 once daily fractions) if - no progressive disease - recovery from surgery - performance status WHO 0-2
16 Mesothelioma trial 1ary endpoint : success of teatment : full protocol, alive after 90 days no progression, no G3 - G4 toxicity 2ary endpoints : overall and progression-free survival, toxicity
17 Mesothelioma trial - results Surgery 46 pts (79.3%) operated; 42 (73.7%) had EPP R0 30 R1 10 R2 3 6 reoperations bleeding hematoma bronchopleural fistula diaphragmatic eventration
18 Mesothelioma trial - results Surgery pt0 2 pt1 5 pt2 19 pt3 15 pt4 4 pn0 34 pn1 2 pn2 6 pnx 2 30 and 90-day 3 pts (6.5%): pulmonary embolism lung edema, pneumonia progressive disease
19 Mesothelioma trial - results Follow-up persisting G3-4 toxicity 90 days after end of protocol treatment: 3 pts (5.3%) radiation pneumonitis 1 bronchopleural fistula 2
20 Mesothelioma trial - results Survival data median follow-up time 19.3 mos (95% CI ) overall MST 18.4 mos (95% CI 14.8-NR) progression-free MST 13.9 mos (95% CI ) Van Schil P et al. Eur Resp J 2010; 36:1362-9
21 Ov erall surv iv al All eligible patients who started their treatment overall MST 18.4 mos (months) O N Number of patients at risk : All Patients N b Patie nts
22 Progression free surv iv al All eligible patients who started their treatment progression-free MST 13.9 mos (months) O N Number of patie nts at risk : All Patients Nb Patie nts
23 Mesothelioma trial results Primary endpoint only 24 pts (42.1%) met definition of success (onesided 90% CI for proportion of success ) reasons for failure at least 2 cycles of ICT not given 1 no EPP 15 no 54 Gy PORT 21 not within time frame 27 mortality 7 persisting G3/4 toxicity 3 progressive disease 16 1ary endpoint not met Van Schil P et al. Eur Resp J 2010; 36:1362-9
24 Malignant pleural mesothelioma surgical treatment surgical techniques, definitions pleurectomy/decortication extrapleural pneumonectomy recent surgical studies EORTC MARS 1 pilot trial surgery: quo vadis?
25 MARS trial (UK) Mesothelioma And Radical Surgery trial 3 cycles of induction chemotherapy, repeat staging eligibility : reviewed by MARS multidisciplinary team randomization : no EPP surgery 670 patients T1-3, N0-1, M0 EPP primary endpoint : survival secondary endpoint : QOL
26 MARS trial (UK) randomized pilot feasibility study : aims : feasibility of randomizing 50 pts. feasibility of undertaking this surgery as a multi-center trial feasibility of surgery 11 centres; 112 pts evaluated and induction therapy 50 pts (45%) randomized randomization feasible between surgical and non-surgical treatment Treasure T. J Thor Oncol 2009; 4:1254-8
27 MARS: trial design Fit for surgery (BTS guidelines) Patient consent and registration Staging: PET & mediastinoscopy 3 cycles of platinum-chemotherapy Repeat staging by CT scan N = 112 Eligibility reviewed by virtual multidisciplinary team N = 57 Patient consent R EPP No EPP N = 24 N = 26 Post-operative radical hemithoracic radiotherapy Treasure et al. Lancet Oncol 2011; 12: Snee et al. J Thoracic Oncol 2011; 6 suppl 2: O 30.07
28 MARS 1 pilot It took 3 years to randomize 50 patients to EPP or no EPP! 3/16 = 18.8% Treasure et al. Lancet Oncol 2011; 12: Snee et al. J Thoracic Oncol 2011; 6 suppl 2: O 30.07
29 MARS: OS No EPP= 13 deaths Median OS: 14m EPP vs 19m no EPP 1-yr OS: 52% EPP vs 73% no EPP adjusted HR: 2.75 ; p EPP= 17 deaths Treasure et al. Lancet Oncol 2011; 12: Snee et al. J Thoracic Oncol 2011; 6 suppl 2: O 30.07
30 MARS: Quality of Life Treasure et al. Lancet Oncol 2011; 12: Snee et al. J Thoracic Oncol 2011; 6 suppl 2: O 30.07
31 MARS: authors conclusions In view of the high morbidity associated with EPP in this trial and in other non-randomized studies a larger study is not feasible. These data, although limited, suggest that radical surgery in the form of EPP within trimodal therapy offers no benefit and possibly harms patients. Thus EPP can no longer be recommended as an option for patients with mesothelioma Treasure et al. Lancet Oncol 2011; 12: Snee et al. J Thoracic Oncol 2011; 6 suppl 2: O 30.07
32 Malignant pleural mesothelioma surgical treatment surgical techniques, definitions pleurectomy/decortication extrapleural pneumonectomy recent surgical studies EORTC MARS 1 pilot trial surgery: quo vadis?
33 P/D is superior to EPP in multimodality management of pts with MPM prospective, non-randomized study 7- year period 2 groups: EPP 25 pts induction CT: cisplatin-gemcitabine or cisplatin-pemetrexed 22 pts EPP (3 abandoned due to extent of disease) 17 pts adj. RT 54 Gy (68% full protocol) P/D 61 pts P/D + hyperthermic pleural lavage (povidone-iodine) 57% macroscopic complete resection 54 pts+ prophylactic RT 21 Gy + adjuvant CT 4-6 cycles Lang-Lazdunski L et al. J Thor Oncol 2012; 7:737-43
34 P/D is superior to EPP in multimodality management of pts with MPM 30-day EPP 4.5% P/D 0% morbidity 68% 28% survival MST EPP 12.8 mos P/D 23 mos 5-year 9% 30.1% p =.004 multivariable analysis: P/D epitheloid histology completeness of resection multimodality setting: P/D superior to EPP Lang-Lazdunski L et al. J Thor Oncol 2012; 7:737-43
35 Is it time to consider P/D as the only surgical treatment for MPM? EPP gold standard until now MARS trial: EPP morbidity - is P/D now standard therapy? to be abandoned «it is too early based on this data to completely abandon EPP altogether» Weyant MJ. Editorial. J Thor Oncol 2012; 7: options: macroscopic complete resection P/D EPP EORTC: randomized phase II of induction versus adjuvant CT + extended P/D in early stage MPM
36 Surgical studies in mesothelioma Conclusions MPM highly lethal disease surgery: role diagnosis, staging, palliation, treatment combined modality treatment indicated in early stages role of induction versus adjuvant chemotherapy? role of maximal debulking by EPP versus P/D? survival advantage of trimodality treatment? further phase II/III multicenter trials necessary
37 Surgical studies in mesothelioma Staging - restaging pleura lung surrounding organs precise estimation tumor volume difficult correct staging : comparative studies treatment and prognosis
38 IMIG 1995 International Mesothelioma Interest Group no classical T N M descriptors until 1995 similar to other solid tumors (NSCLC) : TNM, stage grouping reconciles previous staging systems, mainly surgically based prospective IASLC database, new proposal Rusch VW (IMIG). Chest 1995; 108: Pleural mesothelioma. AJCC cancer staging handbook, Springer, 2002
39 Restaging MPM how to evaluate response after chemo-, chemoradiotherapy? neoadjuvant therapy: surgery assessment of response non-invasive: subsequent CT scans role of PET? WHO, RECIST criteria inadequate for MPM WHO: perpendicular diameters of tumor nodules RECIST: unidimensional, longest diameter of tumor - applies for spherical tumors Van Klaveren R. Lung Cancer 2004; 43:63-69 Monetti F. Lung Cancer 2004; 43:71-74
40 MPM response evaluation modified RECIST RECIST longest diameter : stable disease modified RECIST perpendicular diameter : partial response Byrne M. Ann Oncol 2004; 15:257-60
41 Surgical studies in mesothelioma landmark trials combined modality therapy 183 pts trimodality : EPP + adjuvant chemotherapy and radiotherapy till 30 Gy mortality : 3.8 % morbidity 50 % MST 19 mos. 5-year survival : 15 % prognostic factors : epithelial cell type, resection margins, extrapleural nodes Sugarbaker DJ. J Thorac Cardiovasc Surg 1999; 117:54
42 Surgical results in mesothelioma total series 496 pts EPP analysis 328 consecutive pts % morbidity 60 % complications: % atrial fibrillation 44.2 prolonged intubation 7.9 vocal cord paralysis 6.7 DVT 6.4 technical complications 6.1 patch dehiscence, hemorrhage, or both Sugarbaker DJ. J Thorac Cardiovasc Surg 2004; 128:138
43 Surgical studies in mesothelioma landmark trials SAKK : Swiss Group for Clinical Cancer Research neoadjuvant chemotherapy 3 cycles cisplatin + gemcitabine 61 pts. T2N2M0 MPM 45/58 patients completing chemotherapy EPP ± radiotherapy (incomplete resection or areas at risk) 37 complete resection (61 %); 36 postop. radiotherapy Opitz I. Eur J Cardiothorac Surg 2006; 29:5744 Weder W. Ann Oncol 2007; 18:1196
44 Surgical studies in mesothelioma landmark trials 90-day 2 pts. (3.2 %) 1 or more complic. in 62 % empyema 16 % bronchopleural fistula 9.5 % 1-year survival : 69 % MST EPP 25.9 mos. Opitz I. Eur J Cardiothorac Surg 2006; 29:5744 Weder W. Ann Oncol 2007; 18:1196 phase II trial : induction chemotherapy + EPP ± PORT
Malignant Pleural Mesothelioma COMBINED TREATMENT
Malignant Pleural Mesothelioma COMBINED TREATMENT Federica Grosso incidence Italy
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Mesothelioma: Live to Fight Another Day Andrea S. Wolf, MD, Raja M. Flores, MD PII: S0022-5223(17)32747-2 DOI: 10.1016/j.jtcvs.2017.11.060 Reference: YMTC 12301 To appear in: The Journal
More informationAccepted Manuscript. Surgery for mesothelioma: less is more, more or less. Steven Milman, MD, Thomas Ng, MD
Accepted Manuscript Surgery for mesothelioma: less is more, more or less Steven Milman, MD, Thomas Ng, MD PII: S0022-5223(17)32706-X DOI: 10.1016/j.jtcvs.2017.11.029 Reference: YMTC 12266 To appear in:
More informationExtrapleural Pneumonectomy: A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma?
Original Research Extrapleural Pneumonectomy: A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma? PLEURA January-December 2015: 1-7 ª The Author(s) 2015 DOI: 10.1177/2373997515595219
More informationMalignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient
Editorial Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient Ori Wald, David J. Sugarbaker Division of General Thoracic Surgery, Michael E. DeBakey
More informationStandardizing surgical treatment in malignant pleural mesothelioma
Perspective Standardizing surgical treatment in malignant pleural mesothelioma David Rice University of Texas M.D. Anderson Cancer Center, Houston, TX, USA Corresponding to: David Rice. University of Texas
More informationOriginal Article. Keywords: Mesothelioma; surgery; platelet
Original Article Clinical role of a new prognostic score using platelet-tolymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy Tetsuzo Tagawa 1,2, Masaki
More informationMalignant pleural mesothelioma (MPM) remains a major
Original Article Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc Lang-Lazdunski, MD*, Andrea Bille,
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationLung Cancer 83 (2014) Contents lists available at ScienceDirect. Lung Cancer. journal homepage:
Lung Cancer 83 (2014) 78 82 Contents lists available at ScienceDirect Lung Cancer journal homepage: www.elsevier.com/locate/lungcan Radical pleurectomy/decortication followed by high dose of radiation
More informationPleurectomy/decortication versus extrapleural pneumonectomy: a critical choice
Editorial Pleurectomy/decortication versus extrapleural pneumonectomy: a critical choice Pier Luigi Filosso, Francesco Guerrera, Paolo Olivo Lausi, Roberto Giobbe, Paraskevas Lyberis, Enrico Ruffini, Alberto
More informationChemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma. A Review and Case Report
STATE OF THE ART: CONCISE REVIEW Chemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma A Review and Case Report Cecilia Bech, MD, and Jens Benn Sørensen, MD, DMSc, MPA Introduction:
More informationThe Imaging Journey of Patients with Malignant Pleural Mesothelioma: Experience of a Tertiary Mesothelioma MDT
The Imaging Journey of Patients with Malignant Pleural Mesothelioma: Experience of a Tertiary Mesothelioma MDT V. Lam, J. Brozik, A. J. Sharkey, A. Bajaj, D. T. Barnes Glenfield Hospital, Leicester, United
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationMalignant pleural mesothelioma (MPM) remains a major
ORIGINAL ARTICLE Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma Loïc Lang-Lazdunski, MD, PhD,
More informationThe role of surgical resection in the management of malignant
ORIGINAL ARTICLE Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER])
More informationMalignant pleural mesothelioma (MPM) has a poor prognosis,
ORIGINAL ARTICLE Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP,* John M. Alvarez, MBBS, FRACS, Jenny Ma Wyatt,
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationExtended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach
Interactive CardioVascular and Thoracic Surgery 25 (2017) 696 702 doi:10.1093/icvts/ivx221 Advance Access publication 21 July 2017 ORIGINAL ARTICLE Cite this article as: Sharkey AJ, Bilancia R, Tenconi
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationTreatment of malignant pleural mesothelioma (MPM)
Original Article A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma A Review of 12 Years Experience Isabelle Opitz, MD,* Martina Friess,
More informationSponsored document from The Lancet Oncology
Sponsored document from The Lancet Oncology Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and
More informationNovel radiation therapy approaches in malignant pleural mesothelioma
Research Highlight Novel radiation therapy approaches in malignant pleural mesothelioma Andreas Rimner 1, Kenneth E. Rosenzweig 2 1 Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center,
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationSystemic Management of Malignant Pleural Mesothelioma
ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN MEDICAL ONCOLOGY 15.June-19.June 2018 Belgrade, Serbia Systemic Management of Malignant Pleural Mesothelioma Dragana Jovanovic University Hospital
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationTherapeutic Surgery for Nonepithelioid Malignant Pleural Mesothelioma: Is it Really Worthwhile?
Therapeutic Surgery for Nonepithelioid Malignant Pleural Mesothelioma: Is it Really Worthwhile? Bram Balduyck, MD, Delphine Trousse, MD, Apostolos Nakas, MD, Antonio E. Martin-Ucar, MD, John Edwards, MD,
More informationClinicopathological and Survival Characteristics of Malignant Pleural Mesothelioma: A Single-Institutional Experience
TURKISH JOURNAL of ONCOLOGY ORIGINAL ARTICLE Clinicopathological and Survival Characteristics of Malignant Pleural Mesothelioma: A Single-Institutional Experience Şule KARABULUT GÜL, 1 Ahmet Fatih ORUÇ,
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationGeneral. for Thoracic Surgery GTS
General Thoracic Surgery Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma Terry T. Lee,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES LUNG SITE MESOTHELIOMA Lung Site Group Mesothelioma Authors: Dr. Meredith Giuliani, Dr. Andrea Bezjak 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationThe 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationMalignant pleural mesothelioma (MPM) is an aggressive
ORIGINAL ARTICLE Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung Emilio Minatel, MD,*
More informationLung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationInduction or adjuvant chemotherapy for radical multimodality therapy
Review Article Page 1 of 8 Induction or adjuvant chemotherapy for radical multimodality therapy Annabel J. Sharkey Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield, UK Correspondence
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationGTS. The Journal of Thoracic and Cardiovascular Surgery c Volume 145, Number 4 955
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationMalignant pleural mesothelioma (MPM) affects nearly
ORIGINAL ARTICLE Patterns of Local and Nodal Failure in Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy and Photon-Electron Radiotherapy Vishal Gupta, MD,* Lee M. Krug, MD, Benjamin Laser,
More informationMalignant pleural mesothelioma (MPM) is an uncommon
Risk Factors for Major Complications After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma Marc de Perrot, MD, Karen McRae, MD, Masaki Anraku, MD, Keyvan Karkouti, MD, Thomas K. Waddell,
More informationCitation for published version (APA): van Ruth, S. (2003). Hyperthermic intracavitary chemotherapy in abdomen and chest
UvADARE (Digital Academic Repository) Hyperthermic intracavitary chemotherapy in abdomen and chest van Ruth, S. Link to publication Citation for published version (APA): van Ruth, S. (2003). Hyperthermic
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationEdinburgh Research Explorer
Edinburgh Research Explorer What Is the Role of Radiotherapy in Malignant Pleural Mesothelioma? Citation for published version: Price, A 2011, 'What Is the Role of Radiotherapy in Malignant Pleural Mesothelioma?'
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationThe incidence of malignant pleural mesothelioma
Operation and Photodynamic Therapy for Pleural Mesothelioma: 6-Year Follow-up Thomas L. Moskal, MD, Thomas J. Dougherty, PhD, John D. Urschel, MD, Joseph G. Antkowiak, MD, Anne-Marie Regal, MD, Deborah
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Mesothelioma
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document
More informationPositron emission tomography predicts survival in malignant pleural mesothelioma
Flores et al General Thoracic Surgery Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, a Timothy Akhurst, MD, b Mithat Gonen, PhD, c Maureen Zakowski,
More informationIntraoperative adjuncts for malignant pleural mesothelioma
Review Article Intraoperative adjuncts for malignant pleural mesothelioma Warren Ho Chan, David J. Sugarbaker, Bryan M. Burt Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationCrossroads Congress in Cardiothoracic Surgery Athens 2018 Malignant Pleural Mesothelioma in the UK: Current Research and Experience
Crossroads Congress in Cardiothoracic Surgery Athens 2018 Malignant Pleural Mesothelioma in the UK: Current Research and Experience Mr Apostolos Nakas Consultant Thoracic Surgeon Head of Department of
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationMalignant pleural mesothelioma (MPM) is an aggressive
Original Article Prospective Study on Functional Results After Lung-Sparing Radical Pleurectomy in the Management of Malignant Pleural Mesothelioma Servet Bölükbas, MD, PhD,* Michael Eberlein, MD, PhD,
More informationPleurectomy-decortication (P/D) was first popularized in
Technique of Pleurectomy and Decortication Andrew J. Kaufman, MD, and Raja M. Flores, MD Pleurectomy-decortication (P/D) was first popularized in the mid 1950s as a surgical method for treating entrapped
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationProlonged post recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma
ONCOLOGY LETTERS Prolonged post recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma YUICHIRO KAI, YASUHIRO TSUTANI, NORIFUMI TSUBOKAWA, MASAOKI ITO, TAKESHI MIMURA,
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationInsights into Thymic Epithelial Tumors: Radiation Therapy
Insights into Thymic Epithelial Tumors: Radiation Therapy Charles R. Thomas, MD Professor and Chairman, Department of Radiation Medicine Professor, Department of Medicine, Division of Hematology/Medical
More informationThe epidemiology of mesothelioma first came to light in
Treatment of Malignant Pleural Mesothelioma: Pleurectomy with Adjuvant Therapy Raja M. Flores, MD,* and Naveed Alam, MD The epidemiology of mesothelioma first came to light in 1960 with the report by Wagner
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationComputed tomography and Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
Computed tomography and Modified RECIST criteria for assessment of response in malignant pleural mesothelioma Poster No.: C-0729 Congress: ECR 2013 Type: Scientific Exhibit Authors: A. Marin, I. Pozek,
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationWell-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report
Showa Univ J Med Sci 25 1, 67 72, March 2013 Case Report Well-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report Yuri TOMITA
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationSurgical Approaches to Locally Advanced NSCLC. Kemp H. Kernstine, MD, PhD Professor and Chairman UT Southwestern Medical Center Dallas, TX
Surgical Approaches to Locally Advanced NSCLC Kemp H. Kernstine, MD, PhD Professor and Chairman UT Southwestern Medical Center Dallas, TX Keep it real simple. Do one thing and do it the best you can. -Harry
More informationRoutine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF)
Routine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF) Abstract The results of 25 cases underwent a pedicled pericardial flap coverage for the bronchial
More informationProtocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma
Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma Based on AJCC/UICC TNM, 7th edition Protocol web posting date: February 1, 2011 Procedures Resection Authors
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationStage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
More informationNeo-adjuvant chemotherapy in NSCLC
SCLC Epidemiology eo-adjuvant chemotherapy in SCLC Sarita Dubey sst Professor, Medical ncology, UCSF UCSF/UC Davis Thoracic conference ovember 8, 2008 Statistics for 2008 Cancer Incidence Deaths Colon
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationVideo assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases
Review Article on Thoracic Surgery Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases Periklis Perikleous, David A. Waller Department of thoracic
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationLung cancer involving neighboring structures is classified
GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka,
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationTrimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
More informationBronchial sleeve lobectomy is a lung parenchyma saving
ORIGINAL ARTICLE Quality of Life after Lung Cancer Surgery: A Prospective Pilot Study comparing Bronchial Sleeve Lobectomy with Pneumonectomy Bram Balduyck, MD, Jeroen Hendriks, MD, PhD, Patrick Lauwers,
More informationCurrent Management of Postpneumonectomy Bronchopleural Fistula
Current Management of Postpneumonectomy Bronchopleural Fistula Shaf Keshavjee MD MSc FRCSC FACS Surgeon-in-Chief, University Health Network James Wallace McCutcheon Chair in Surgery Professor, Division
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationEvaluation of Lung Cancer Response: Current Practice and Advances
Evaluation of Lung Cancer Response: Current Practice and Advances Jeremy J. Erasmus I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of
More informationProf. Lorenzo Spaggiari
Prof. Lorenzo Spaggiari Personal Information Date of Birth: May 9,1961at CASINA (Reggio Emilia,Italy) Address of residence or domicile: Via G. Antonini 32, 20141Milan,Italy E-mail : lorenzo.spaggiari@ieo.it
More information